P53 and induction of apoptosis as a target for anticancer therapy

Leukemia

Volumn 10, Issue SUPPL. 3, 1996, Pages

  Neubauer, A ^a   Thiede, C ^a   Huhn, D ^a   Wittig, B ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Apoptosis; Cancer; Chemotherapy resistance; Leukemia; p53

Indexed keywords

PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; CONFERENCE PAPER; DELETION MUTANT; GENE MUTATION; GENE THERAPY; HUMAN; MYELOID LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SYNTHESIS;

EID: 0029839850     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (46)

1. Korsmeyer SJ. BCL-2 initiates a new category of oncogenes: regulators of cell deaths. Blood 1992; 80: 879-886.
2. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992; 70: 523-526.
3. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-299.
4. Buckbinder L, Talbott R, Velasco-Miguel S, Takenada I, Faha B, Seizinger BR, Kley N. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995; 377: 646-649.
5. Lee JM, Bernstein A. p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA 1993; 90: 5742-5746.
6. Bristow RG, Jang A, Peacock J, Chung S, Benchimol S, Hill RP. Mutant p53 increases radioresistance in rat embryo fibroblasts simultaneously transfected with HPV16-E7 and/or activated H-ras. Oncogene 1994; 9: 1527-1536.
7. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304-6311.
8. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362: 847-849.
9. Jayaraman J, Prives C. Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell 1995; 81: 1021-1029.
10. Lane DP. p53, a guardian of the genome. Nature 1992; 358: 15-16.
11. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-967.
12. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266: 807-810.
13. Döhner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, Diehl D, Schlenk R, Coy J, Stilgenbauer S, Volkmann M, Galle PR, Poustka A, Hunstein W, Lichter P. 3 gene deletions predicts for a poor survival and non-response to therapy with purine analogs in chronic B-cell leukemia. Blood 1995; 85: 1580-1589.
14. Caelles C, Heimberg A, Karin M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 1994; 370: 220-223.
15. Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, Roth JA, Deisseroth AB, Zhang WW, Kruzel E et al. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 1995; 15: 3032-3040.
16. Agarwal ML, Agarwal A, Taylor WR, Stark GR. p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA 1995; 92: 8493-8497.
17. Guillouf C, Rosselli F, Krishnaraju K, Moustacchi E, Hoffman B, Liebermann DA. p53 involvement in control of G2 exit of the cell cycle: role in DNA damage-induced apoptosis. Oncogene 1995; 10: 2263-2270.
18. El-Deiry WS, Velculesco VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.
19. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701-704.
20. Di-Leonardo A, Linke SP, Clarkin K, Wahl GM. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev 1994; 8: 2540-2551.
21. Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P, Dobrowolski S, Bai C, Connell-Crowley L, Swindell E et al. Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 1995; 6: 387-400.
22. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994; 369: 574-578.
23. Chen LC, Neubauer A, Kurisu W, Waldman F, Ljung BM, Goodson W, Goldman E, Moore D, Balazs M, Liu E, Mayall B, Smith HS. Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and DNA aneuploidy in primary human breast cancer. Proc Natl Acad Sci USA 1991; 88: 3847-3851.
24. Adamson DJA, Thompson WD, Dawson AA, Bennett B, Haites NE. p53 mutation and expression in lymphoma. Br J Cancer 1995; 72: 150-154.
25. Millikan R, Hulka B, Thor A, Zhang Y, Edgerton S, Zhang X, Pei H, He M, Wold L, Melton LJ, Ballard D, Conway K, Liu ET. p53 mutations in benign breast tissue. J Clin Oncol 1995; 13: 2293-2300.
26. Runnebaum IB, Nagarajan M, Bowman M, Soto D, Sukumar S. Mutations in p53 as potential molecular markers for human breast cancer. Proc Natl Acad Sci USA 1991; 88: 10657-10661.
27. Thompson AM, Anderson TJ, Condie A, Prosser J, Chetty U, Carter DC, Evans HJ, Steel CM. p53 allele losses, mutations and expression in breast cancer and their relationship to clinico-pathological parameters. Int J Cancer 1992; 50: 528-532.
28. Iwaya K, Tsuda H, Hiraide H, Tamaki K, Tamakuma S, Fukutomi T, Mukai K, Hirohashi S. Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn J Cancer Res 1991; 82: 835-840.
29. Hamilton SR. Molecular genetic alterations as potential prognostic indicators in colorectal carcinoma. Cancer 1992; 69: (Suppl.): 1589-1591.
30. Bergh J, Norberg T, Sjögren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Med 1995; 1: 1029-1034.
31. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature 1991; 352: 345-347.
32. Blandino G, Scardigli R, Rizzo MG, Crescenzi M, Soddu S, Sacchi A. Wild-type p53 modulates apoptosis of normal, IL-3 deprived, hematopoietic cells. Oncogene 1995; 10: 731-737.
33. Srivasta S, Zou Z, Pirollo K, Blattner W, Change EH. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990; 348: 747-749.
34. Fenaux P, Preudhomme C, Quiquandon I, Jonveaux P, Lai JL, Vanrumbeke M, Loucheux-Lefebvre M, Bauters F, Berger R, Kerckaert JP. Mutations of the p53 gene in acute myeloid leukemia. Br J Haematol 1992; 80: 178-183.
35. Fenaux P, Jonveaux P, Quiquandon I, Lai JL, Pignon JM, Loucheux-Lefebre MH, Bauters F, Berger R, Kerckaert JP. p53 gene mutation in acute myeloid leukemia with monosomy 17p. Blood 1991; 78: 1652-1657.
36. Lai JL, Preudhomme C, Zandecki M, Flactif M, Vanrumbeke M, Lepelley P, Wattel E, Fenaux P. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of p53 mutations. Leukemia 1995; 9: 370-381.
37. Schottelius A, Brennscheidt U, Ludwig WD, Mertelsmann RH, Herrmann F, Lübbert M. Mechanisms of p53 alterations in acute leukemias. Leukemia 1994; 8: 1673-1681.
38. Neubauer A, Brendel C, Vogel D, Schmidt CA, Heide I, Huhn D. Detection of p53 mutations using non-radioactive SSCP-analysis: p53 is not frequently mutated in myelodysplastic syndromes. Ann Hematol 1993; 67: 223-226.
39. Lesoon-Wood LA, Kim WH, Kleinman HK, Weintraub BD, Mixson AJ. Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. Hum Gene Ther 1995; 6: 395-405.
40. Liu TJ, Zhang WW, Taylor DL, Roth JA, Goepfert H, Clayman GL. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res 1994; 54: 3662-3667.
41. Zhang WW, Fang X, Mazur W, French BA, Georges RN, Roth JA. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1994; 1 (1): 5-13.
42. Sinkovics J, Horvath J. Apoptosis by genetic engineering. Leukemia 1994; 8 (Suppl 1): S98-102.
43. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994; 265: 346-355.
44. Vogelstein B, Kinzler KW. X-ray strikes p53 again. Nature 1994; 370: 174-175.
45. Ory K, Legros Y, Auguin C, Soussi T. Analysis of the most representative tumour-derived p53 mutations reveals that changes in protein conformation are not correlated with loss of transcativation or inhibition of cell proliferation. EMBO J 1994; 13: 3496-3504.
46. Bedi A, Barber JP, Bedi GC, el-Deiry WS, Sidransky D, Vala MS, Akhtar AJ, Hilton J, Jones RJ. BCR-ABL mediated inhibition of apoptosis with delay of G2/M after DNA damage: a mechanism of resistance to anticancer agents. Blood 1995; 86: 1148-1153.